Topic resource collection
Approved comparison material connected to this topic.
3 resourcesRead both sides
The peptide market expanded rapidly in 2025–2026, and with it came exaggerated claims. BPC-157 has human trial data for tendon healing and gastric ulcer repair. It does not have Phase 3 human data specifically for osteoarthritis …
Before diving into scenario-based applications, here's how the primary joint pain peptides compare across mechanism, dosing, evidence grade, and practical use cases. BPC-157 COL2A1 upregulation, mTOR-independent collagen synthesi…
BPC-157 VEGF upregulation, FAK-paxillin pathway activation. Promotes angiogenesis and collagen synthesis 250–500 mcg daily, subcutaneous or intramuscular 2–4 weeks for tendon/ligament symptoms Acute tendinopathy, ligament sprains…